Citadel Advisors Portfolio holdings
Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 82.83% |
| 2 | Healthcare | 3.13% |
| 3 | Technology | 2.97% |
| 4 | Financials | 2.19% |
| 5 | Consumer Discretionary | 2.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
12601
PUT
Anixa Biosciences
ANIX
$105M
| $38.7K | ﹤0.01% |
16,700
+10,000
| +149% | +$31.1K |
2024 Q3
1 quarter
|
|
12602
CALL
Oric Pharmaceuticals
ORIC
$1.24B
| $38.7K | ﹤0.01% |
4,800
-3,000
| -38% | -$27.5K |
2024 Q3
1 quarter
|
|
12603
PUT
X4 Pharmaceuticals
XFOR
$275M
| $38.7K | ﹤0.01% |
1,760
+1,020
| +138% | +$16.3K |
2021 Q3
13 quarters
|
|
12604
CALL
Arteris
AIP
$1.19B
| $38.7K | ﹤0.01% |
3,800
-19,100
| -83% | -$158K |
2023 Q1
7 quarters
|
|
12605
CALL
WisdomTree Yield Enhanced US Aggregate Bond Fund
AGGY
$894M
| $38.6K | ﹤0.01% |
900
-1,500
| -63% | -$65.5K |
2024 Q3
1 quarter
|
|
12606
CALL
Future Fuel
FF
$226M
| $38.6K | ﹤0.01% |
7,300
+4,300
| +143% | +$24K |
2021 Q2
14 quarters
|
|
12607
PUT
Fulton Financial
FULT
$4.28B
| $38.6K | ﹤0.01% |
2,000
| – | – |
2022 Q4
8 quarters
|
|
12608
Xilio Therapeutics
XLO
$59.2M
| $38.5K | ﹤0.01% |
+2,880
| New | +$39.6K |
2024 Q4
0 quarters
|
|
12609
CALL
Oportun Financial
OPRT
$383M
| $38.4K | ﹤0.01% |
9,900
-23,400
| -70% | -$75.5K |
2022 Q2
10 quarters
|
|
12610
PUT
ALX Oncology
ALXO
$153M
| $38.4K | ﹤0.01% |
23,000
+16,000
| +229% | +$24.6K |
2022 Q4
8 quarters
|
|
12611
PUT
Solid Biosciences
SLDB
$742M
| $38.4K | ﹤0.01% |
9,600
+3,200
| +50% | +$17.6K |
2024 Q1
3 quarters
|
|
|
PHLT
12612
DELISTED
Performant Healthcare Inc
PHLT
| $38.4K | ﹤0.01% |
12,709
-38,453
| -75% | -$132K |
2024 Q1
3 quarters
|
|
12613
CALL
Astronics
ATRO
$2.97B
| $38.3K | ﹤0.01% |
2,880
-1,560
| -35% | -$22.9K |
2022 Q4
8 quarters
|
|
12614
CALL
Ducommun
DCO
$2.65B
| $38.2K | ﹤0.01% |
600
-1,100
| -65% | -$70.6K |
2022 Q4
8 quarters
|
|
12615
PUT
Repay Holdings
RPAY
$318M
| $38.1K | ﹤0.01% |
5,000
-5,800
| -54% | -$46.3K |
2024 Q3
1 quarter
|
|
12616
CALL
Southside Bancshares
SBSI
$900M
| $38.1K | ﹤0.01% |
1,200
-200
| -14% | -$6.79K |
2022 Q4
8 quarters
|
|
12617
CALL
KraneShares Global Carbon Strategy ETF
KRBN
$136M
| $38.1K | ﹤0.01% |
1,300
+800
| +160% | +$24.7K |
2024 Q3
1 quarter
|
|
|
CRSH
12618
CALL
YieldMax Short TSLA Option Income Strategy ETF
CRSH
$13.6M
| $38K | ﹤0.01% |
+620
| New | +$58.5K |
2024 Q4
0 quarters
|
|
12619
Urban One Class A
UONE
$19.1M
| $37.9K | ﹤0.01% |
+2,461
| New | +$37.3K |
2024 Q4
0 quarters
|
|
12620
CALL
Greenlight Captial
GLRE
$478M
| $37.8K | ﹤0.01% |
2,700
-9,400
| -78% | -$133K |
2023 Q4
4 quarters
|
|
12621
PUT
Gerdau
GGB
$10B
| $37.7K | ﹤0.01% |
13,100
-11,700
| -47% | -$38.6K |
2016 Q2
34 quarters
|
|
12622
CALL
Beam Global
BEEM
$25.1M
| $37.7K | ﹤0.01% |
11,900
+4,300
| +57% | +$17.7K |
2021 Q1
15 quarters
|
|
12623
CALL
GoodRx Holdings
GDRX
$1.12B
| $37.7K | ﹤0.01% |
8,100
-120,300
| -94% | -$661K |
2020 Q4
16 quarters
|
|
12624
CALL
Compugen
CGEN
$210M
| $37.6K | ﹤0.01% |
24,600
+15,200
| +162% | +$24.7K |
2023 Q2
6 quarters
|
|
12625
ProShares UltraShort FTSE China 50 of ProShares Trust
FXP
$5.69M
| $37.6K | ﹤0.01% |
+1,037
| New | +$37.5K |
2024 Q4
0 quarters
|
|
Similar funds
Citadel Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, Citadel Advisors held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Citadel Advisors's Q4 2024 filing shows 1,745 new, 6,427 increased, 6,082 reduced and 1,421 closed positions. Its largest new stake was Zoetis: 1,090,499 shares worth $178M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B.
By sector, the portfolio is most concentrated in Miscellaneous at 83% of assets, down from 83% a quarter earlier, followed by Healthcare and Technology.
- Citadel Advisors's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Citadel Advisors added most to Boeing in Q4 2024, an estimated $830M increase.
- Citadel Advisors's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Citadel Advisors fully exited Spotify in Q4 2024, selling an estimated $473M.
- Citadel Advisors's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Citadel Advisors opened 1,745 new positions and closed 1,421 in Q4 2024.
- Citadel Advisors's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.